Simvastatin does not prevent acute cardiac allograft rejection in CD28-deficient mice

Schramm, René; Schmits, Rudolph; Schäfers, Hans‐Joachim; Menger, Michael D.

doi:10.1007/s00011-009-0045-3

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is difficult to interpret such negative data in the face of other well‐conducted studies that report positive results, but in the meantime, to an increasing extent, reports are accumulating which do not confirm the protective effect of statins [Schramm et al, ]. Other studies confirm the results of the current study.…”

Section: Discussioncontrasting

confidence: 66%

Simvastatin treatment showed no prophylactic effect in influenza virus‐infected mice

Glück

Schmidtke

Walther

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

Simvastatin, a cholesterol-lowering drug, is reported to have immunomodulatory properties that attenuated acute lung injury independent of their major lipid lowering effects. Based on these reports, simvastatin is expected to be used for influenza prophylaxis and treatment. The present study evaluated the efficacy of simvastatin against influenza A/PR/8/34 virus infection in a murine model. In a first study, simvastatin was administered orally. To achieve high plasma levels, intraperitoneal application was used in a second study. Survival, body weight loss, viral titers in lung and trachea, and histologic lung injury were measured. Surprisingly, treatment with simvastatin resulted in lower survival rates and in more distinct body mass loss in comparison to virus-infected control mice. Furthermore, the viral load in lungs and tracheas as well as histopathological lesions were not reduced by simvastatin. Overall, these results showed that simvastatin failed to protect mice against influenza virus infection.

show abstract

Section: Discussioncontrasting

confidence: 66%

Simvastatin treatment showed no prophylactic effect in influenza virus‐infected mice

Glück

Schmidtke

Walther

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…This offers an easily applicable transplantation model with excellent access to the transplanted graft for IVM [12,19,21] . Blood results of hamster-to-rat cardiac xenotransplantation in group 1 after 90 min IVM, in group 2 after long-term survival and in group 3 after sensitisation.…”

Section: Discussionmentioning

confidence: 99%

The coronary microcirculation in hamster-to-rat cardiac xenografts

Buchholz¹,

Geiger²,

Michel³

et al. 2013

Thorac cardiovasc Surg

View full text Add to dashboard Cite

Background:The aim of this study was to establish a new experimental model to directly analyse the coronary microcirculation in cardiac xenografts. Methods: Intravital fluorescence microscopy (IVM) of the subepicardial microcirculation in heterotopically transplanted hamster-to-rat cardiac xenografts was performed at 30 and 90 min of reperfusion. We quantitatively assessed the microcirculatory perfusion characteristics as well as the interactions of leukocytes and platelets with the endothelium of postcapillary coronary venules in non-sensitised as well as sensitised recipients. Results: In this first experimental IVM study of cardiac xenografts, we successfully visualised the subepicardial microcirculation, i.e. feeding arterioles, nutritive capillaries and draining postcapillary venules, during reperfusion. Leukocyteendothelial and platelet-endothelial cell interactions could be quantified. In the non-sensitised group, the myocardial microcirculation remained stable during the observation period of 90 min, whereas in the sensitised group, xenografts were rejected immediately. Conclusions: We established a model for the assessment of the microcirculatory dysfunction and inflammation during ischaemia/reperfusion injury in hamster-to-rat cardiac xenografts.

show abstract

“…This offers an easily applicable transplantation model with excellent access to the transplanted graft for IVM [12,19,21]. …”

Section: Discussionmentioning

confidence: 99%

The Coronary Microcirculation in Hamster-to-Rat Cardiac Xenografts

Geiger

Buchholz²,

Michel³

et al. 2015

Eur Surg Res

Self Cite

View full text Add to dashboard Cite

Background: The aim of this study was to establish a new experimental model to directly analyse the coronary microcirculation in cardiac xenografts. Methods: Intravital fluorescence microscopy (IVM) of the subepicardial microcirculation in heterotopically transplanted hamster-to-rat cardiac xenografts was performed at 30 and 90 min of reperfusion. We quantitatively assessed the microcirculatory perfusion characteristics as well as the interactions of leukocytes and platelets with the endothelium of postcapillary coronary venules in non-sensitised as well as sensitised recipients. Results: In this first experimental IVM study of cardiac xenografts, we successfully visualised the subepicardial microcirculation, i.e. feeding arterioles, nutritive capillaries and draining postcapillary venules, during reperfusion. Leukocyte-endothelial and platelet-endothelial cell interactions could be quantified. In the non-sensitised group, the myocardial microcirculation remained stable during the observation period of 90 min, whereas in the sensitised group, xenografts were rejected immediately. Conclusions: We established a model for the assessment of the microcirculatory dysfunction and inflammation during ischaemia/reperfusion injury in hamster-to-rat cardiac xenografts.

show abstract

Simvastatin does not prevent acute cardiac allograft rejection in CD28-deficient mice

Cited by 3 publications

References 30 publications

Simvastatin treatment showed no prophylactic effect in influenza virus‐infected mice

Simvastatin treatment showed no prophylactic effect in influenza virus‐infected mice

The coronary microcirculation in hamster-to-rat cardiac xenografts

The Coronary Microcirculation in Hamster-to-Rat Cardiac Xenografts

Contact Info

Product

Resources

About